Switch theme
Sign up to access all valuation multiples
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
2015
45
LTM Revenue $46.9M
Last FY EBITDA -$18.2M
$153M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Fulcrum Therapeutics has a last 12-month revenue (LTM) of $46.9M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Fulcrum Therapeutics achieved revenue of $80.0M and an EBITDA of -$18.2M.
Fulcrum Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Fulcrum Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $46.9M | XXX | $80.0M | XXX | XXX | XXX |
| Gross Profit | $46.9M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$18.2M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -23% | XXX | XXX | XXX |
| EBIT | -$47.2M | XXX | -$19.8M | XXX | XXX | XXX |
| EBIT Margin | -101% | XXX | -25% | XXX | XXX | XXX |
| Net Profit | -$36.2M | XXX | -$9.7M | XXX | XXX | XXX |
| Net Margin | -77% | XXX | -12% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Fulcrum Therapeutics's stock price is $7.
Fulcrum Therapeutics has current market cap of $371M, and EV of $153M.
See Fulcrum Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $153M | $371M | XXX | XXX | XXX | XXX | $-0.58 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Fulcrum Therapeutics has market cap of $371M and EV of $153M.
Fulcrum Therapeutics's trades at 1.9x EV/Revenue multiple, and -8.4x EV/EBITDA.
Equity research analysts estimate Fulcrum Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Fulcrum Therapeutics has a P/E ratio of -10.2x.
See valuation multiples for Fulcrum Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $371M | XXX | $371M | XXX | XXX | XXX |
| EV (current) | $153M | XXX | $153M | XXX | XXX | XXX |
| EV/Revenue | 3.3x | XXX | 1.9x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -8.4x | XXX | XXX | XXX |
| EV/EBIT | -3.2x | XXX | -7.7x | XXX | XXX | XXX |
| EV/Gross Profit | 3.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | -10.2x | XXX | -38.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -61.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialFulcrum Therapeutics's last 12 month revenue growth is -100%
Fulcrum Therapeutics's revenue per employee in the last FY averaged $1.8M, while opex per employee averaged $2.2M for the same period.
Fulcrum Therapeutics's rule of 40 is -3968% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Fulcrum Therapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Fulcrum Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -100% | XXX | -94% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -23% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -3968% | XXX | -123% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.8M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $2.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 79% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 125% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Fulcrum Therapeutics acquired XXX companies to date.
Last acquisition by Fulcrum Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Fulcrum Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Fulcrum Therapeutics founded? | Fulcrum Therapeutics was founded in 2015. |
| Where is Fulcrum Therapeutics headquartered? | Fulcrum Therapeutics is headquartered in United States of America. |
| How many employees does Fulcrum Therapeutics have? | As of today, Fulcrum Therapeutics has 45 employees. |
| Who is the CEO of Fulcrum Therapeutics? | Fulcrum Therapeutics's CEO is Mr. Alex C. Sapir. |
| Is Fulcrum Therapeutics publicy listed? | Yes, Fulcrum Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Fulcrum Therapeutics? | Fulcrum Therapeutics trades under FULC ticker. |
| When did Fulcrum Therapeutics go public? | Fulcrum Therapeutics went public in 2019. |
| Who are competitors of Fulcrum Therapeutics? | Similar companies to Fulcrum Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Fulcrum Therapeutics? | Fulcrum Therapeutics's current market cap is $371M |
| What is the current revenue of Fulcrum Therapeutics? | Fulcrum Therapeutics's last 12 months revenue is $46.9M. |
| What is the current revenue growth of Fulcrum Therapeutics? | Fulcrum Therapeutics revenue growth (NTM/LTM) is -100%. |
| What is the current EV/Revenue multiple of Fulcrum Therapeutics? | Current revenue multiple of Fulcrum Therapeutics is 3.3x. |
| Is Fulcrum Therapeutics profitable? | Yes, Fulcrum Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
